Pediatric Brain Tumors: Conformal Radiation Therapy Perspective
Childhood cancer is the most common cause of disease related death among children ages 0 to 19 years.It has not been defined as a public health problem because fewer than 12,500 cases are diagnosed each year. CNS tumors represent 21% of childhood cancers or about 2700 cases per year . This rare group of tumors is composed of astrocytoma, 56% (n = 1510); embryonal tumors including medulloblastoma, supratentorial primitive neuroectodermal tumor, and pineoblastoma, 20% (n = 550); ependymoma, 7% (n = 190); craniopharyngioma, 3% (n = 100); germ cell tumors, 3% (n = 100); and tumors involving the spinal cord, pituitary, and choroid plexus, 11% (n = 300) (Fig. 31-1).
KeywordsPlan Target Volume Posterior Fossa Radiat Oncol Biol Phys Gross Tumor Volume Pediatric Brain Tumor
Unable to display preview. Download preview PDF.
- 1.Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995. National Cancer Institute, SEER Program. NIH Publication No. 99-4649. Bethesda, MD: NIH, 1999.Google Scholar
- 5.Merchant TE, Kun LE, Krasin MJ, et al. A multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys 2003;57:S194–195.Google Scholar
- 7.National Cancer Institute. Phase III randomized adjuvant study of standard-dose versus reduced-dose craniospinal radiotherapy and posterior fossa boost versus tumor bed boost radiotherapy in combination with chemotherapy comprising vincristine, cisplatin, lomustine, and cyclophosphamide in pediatric patients with newly diagnosed standard-risk medulloblastoma. Available at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=365506&protocolsearchid=1695050&version=healthprofessional. Accessed August 10, 2006.Google Scholar
- 8.National Cancer Institute. Phase III study of cyclophosphamide, vincristine, cisplatin, and etoposide followed by second-look surgery and focal conformal radiotherapy in children with nonmetastatic medulloblastoma or posterior fossa primitive neuro ectodermal tumor. Available at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=68269&version=HealthProfessional&protocolsearchid=1695054. Accessed August 10, 2006.Google Scholar
- 9.ICRU Report 50. Dose specification for reporting external beam therapy with photons and electrons. No. 9. Washington, DC: International Commission on Radiation Units and Measurements, 1993.Google Scholar
- 10.ICRU Report 62. Dose specification for reporting external beam therapy with photons and electrons. Washington, DC: International Commission on Radiation Units and Measurements, 1999.Google Scholar
- 11.Leung W, Rose SR, Merchant TE. In Schwartz C, Hobbie W, Constine L, Ruccione K, eds. Survivors of Childhood Cancer: Assessment and Management, 2nd ed. Heidelberg: Springer-Verlag, 2005:51–80.Google Scholar
- 14.Garvin J, Sposto R, Stanley P, et al. Childhood ependymoma: improved survival for patients with incompletely resected tumors with the use of pre-irradiation chemotherapy. 11th International Symposium on Pediatric Neuro-Oncology, Boston, 2004 (abstract THER 29). Available at http://home.comcast.net/~turne038/abstracts.htm. Accessed August 10, 2006.Google Scholar
- 15.National Cancer Institute. Phase II study of conformal radiotherapy for pediatric patients with localized ependymoma, chemotherapy prior to second surgery in pediatric patients with incompletely resected ependymoma, and observation only in pediatric patients with completely resected differentiated, supratentorial ependymoma. Available at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=69086&protocolsearchid=1694995&version=healthprofessional. Accessed August 10, 2006.Google Scholar
© Springer Science+Business Media, LLC 2008